Quality is supported by connected systems—from donor eligibility and tissue practice to controlled manufacturing, batch testing and traceability.
Good Manufacturing Practice is a system for consistently producing and controlling products according to quality standards. It covers premises, equipment, personnel, written procedures, production and quality control.
Its importance lies in controlling process-related risks that cannot be addressed by final-product testing alone.
GTP covers the donation, procurement, testing, processing, preservation, storage, distribution and traceability of human cells and tissues.
It helps protect tissue integrity and reduce risks involving contamination, donor eligibility, mix-ups and loss of traceability.
CGTP refers to Cell and Gene Therapy Products within Malaysia’s regulatory framework. The category helps define how products are classified, documented, manufactured and reviewed.
The relevant product, activity, facility scope and regulatory pathway must be considered together.
A Certificate of Analysis records the tests, specifications and results associated with a defined product batch.
It is important because it connects quality-testing and release information to the batch intended for clinical receipt.
Informed donation and donor eligibility review
Applicable health-risk and infectious-disease screening
Post-delivery hospital collection under the approved programme
Controlled transport, laboratory receipt and Wharton’s jelly processing
Cell processing, quality testing, batch release and COA
Educational summary informed by current Malaysia MOH and NPRA guidance. Facility and document status should be verified for the actual provider and batch.